论文部分内容阅读
目的研究并分析治疗子宫瘢痕妊娠患者时使用介入栓塞术联合不同化疗药物的治疗效果。方法收集2012年3月—2017年1月收治的子宫瘢痕妊娠患者72例作为研究对象,随机分为对照组和观察组各36例。对照组接受介入栓塞术联合甲氨蝶呤治疗,观察组接受介入栓塞术联合卡铂治疗。观察和对比两组平均住院时间、血β-人绒毛膜促性腺激素水平恢复正常时间、不良反应发生情况。计量资料采用t检验,等级资料采用秩和检验,P<0.05为差异有统计学意义。结果观察组的平均住院时间为(6.20±1.63)d,显著短于对照组的(8.13±1.47)d,差异有统计学意义(P<0.05)。观察组的血β-人绒毛膜促性腺激素水平恢复正常时间为(27.04±6.86)d,显著短于对照组的(31.17±6.82)d,差异有统计学意义(P<0.05)。两组不良反应发生情况比较差异无统计学意义(P>0.05)。结论在子宫瘢痕妊娠患者的治疗过程中,介入栓塞术联合卡铂能够迅速降低血β-人绒毛膜促性腺激素水平,缩短患者的住院时间,且不良反应轻微,值得推广应用。
Objective To study and analyze the therapeutic effect of interventional embolization combined with different chemotherapeutic drugs in the treatment of patients with uterine scar pregnancy. Methods Seventy-two patients with uterine scar pregnancy who were treated from March 2012 to January 2017 were randomly divided into control group and observation group of 36 cases. The control group received interventional embolization combined with methotrexate, and the observation group received interventional embolization combined with carboplatin. The mean length of stay, blood β-human chorionic gonadotropin level returned to normal, and adverse reactions were observed and compared. Measurement data using t test, rank data using rank sum test, P <0.05 for the difference was statistically significant. Results The average length of stay in the observation group was (6.20 ± 1.63) d, which was significantly shorter than that in the control group (8.13 ± 1.47) d, with significant difference (P <0.05). The level of β-human chorionic gonadotropin in observation group returned to normal (27.04 ± 6.86) d, which was significantly shorter than that in control group (31.17 ± 6.82) d, the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion In the treatment of patients with uterine scar pregnancy, interventional embolization combined with carboplatin can rapidly reduce the blood β-human chorionic gonadotropin levels, shorten the hospital stay of patients, and mild adverse reactions, it is worth promoting the application.